What does this research mean for the field?

Pumecitinib nasal spray at doses of 1.2 mg and 2.0 mg twice daily significantly reduces nasal and ocular symptoms and improves quality of life in patients with moderate-to-severe seasonal allergic rhinitis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

To evaluate the efficacy, safety, and pharmacokinetics of pumecitinib nasal spray administered over 14 days in patients with moderate-to-severe seasonal allergic rhinitis during pollen season.

August 25, 2026The Lancet Regional Health - Western PacificOpen Access

Efficacy, safety, and pharmacokinetics of pumecitinib nasal spray for moderate-to-severe seasonal allergic rhinitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

View Full Paper

Ask AI

Bookmark

Authors

JLJingyun Li MWMenglin Wang XZXu Zhang

Discussion

Member takes

Overview

Randomized double-blind trial reveals pumecitinib nasal spray reduces nasal and ocular symptoms in seasonal allergic rhinitis, highlighting topical JAK inhibition as an effective therapeutic strategy.

Key Points

To evaluate the efficacy, safety, and pharmacokinetics of pumecitinib nasal spray administered over 14 days in patients with moderate-to-severe seasonal allergic rhinitis during pollen season.
Conducted a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial across 20 centres in China (ChiCTR2400081767).
Randomised 169 adults aged 18–65 years (168 treated; 92 male, 76 female) 1:1:1:1 to receive twice-daily placebo or pumecitinib nasal spray at doses of 0.2 mg, 1.2 mg, or 2.0 mg for 14 days.
Pumecitinib 1.2 mg and 2.0 mg twice daily significantly improved the primary endpoint of mean change in daily reflective total nasal symptom score over 14 days compared with placebo (LS mean difference −1.2 [95% CI −2.2 to −0.2], p=0.021, and −1.2 [95% CI −2.2 to −0.2], p=0.018, respectively).
Both the 1.2 mg and 2.0 mg dosage groups showed significant improvements over placebo in secondary endpoints, including total ocular symptoms, individual symptoms, and quality of life scores.
Treatment-emergent adverse events occurred in 15% (0.2 mg), 33% (1.2 mg), 21% (2.0 mg), and 24% (placebo) of participants, with the majority being mild and showing no dose-response relationship.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a8d4a15e8bd2413309bbf72 https://doi.org/10.1016/j.lanwpc.2026.101969

View Full Paper

Ask AI

Bookmark

August 25, 2026The Lancet Regional Health - Western PacificOpen Access

Efficacy, safety, and pharmacokinetics of pumecitinib nasal spray for moderate-to-severe seasonal allergic rhinitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

View Full Paper

Ask AI

Bookmark

Authors

JLJingyun Li MWMenglin Wang XZXu Zhang

Discussion

Member takes

Overview

Key Points

To evaluate the efficacy, safety, and pharmacokinetics of pumecitinib nasal spray administered over 14 days in patients with moderate-to-severe seasonal allergic rhinitis during pollen season.
Conducted a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial across 20 centres in China (ChiCTR2400081767).
Randomised 169 adults aged 18–65 years (168 treated; 92 male, 76 female) 1:1:1:1 to receive twice-daily placebo or pumecitinib nasal spray at doses of 0.2 mg, 1.2 mg, or 2.0 mg for 14 days.
Pumecitinib 1.2 mg and 2.0 mg twice daily significantly improved the primary endpoint of mean change in daily reflective total nasal symptom score over 14 days compared with placebo (LS mean difference −1.2 [95% CI −2.2 to −0.2], p=0.021, and −1.2 [95% CI −2.2 to −0.2], p=0.018, respectively).
Both the 1.2 mg and 2.0 mg dosage groups showed significant improvements over placebo in secondary endpoints, including total ocular symptoms, individual symptoms, and quality of life scores.
Treatment-emergent adverse events occurred in 15% (0.2 mg), 33% (1.2 mg), 21% (2.0 mg), and 24% (placebo) of participants, with the majority being mild and showing no dose-response relationship.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a8d4a15e8bd2413309bbf72 https://doi.org/10.1016/j.lanwpc.2026.101969

View Full Paper

Ask AI

Bookmark